Nanomedicine Author Guidelines

This document outlines how to prepare articles for submission. We recommend you read these guidelines in full before submitting your article or making an article proposal.

Table of Contents
Journal aims & scope ......................................................................................................................... 4
Audience .................................................................................................................................................. 4
At-a-glance article formatting checklist .................................................................................................. 5
Article types ............................................................................................................................................... 6
Reviews .................................................................................................................................................... 6
Perspectives ............................................................................................................................................... 6
Special Reports ......................................................................................................................................... 7
Original Research Articles ...................................................................................................................... 7
Editorials ................................................................................................................................................... 9
Commentaries .......................................................................................................................................... 10
Interviews .................................................................................................................................................. 10
Journal Watch ......................................................................................................................................... 10
Conference Reports ............................................................................................................................... 10
Company Profiles .................................................................................................................................. 11
Letters to the Editor ................................................................................................................................. 11
Drug, Device & Vaccine Evaluations ....................................................................................................... 11
Clinical Trial Protocols & Clinical Trial Evaluations .............................................................................. 11
Article sections ......................................................................................................................................... 12
Title ....................................................................................................................................................... 12
Author(s) names & affiliations .................................................................................................................. 12

Future Medicine Ltd, Unitec House, 2 Albert Place, London, N3 1QB, UK; T: +44 (0)20 8371 6090; F: +44 (0)20 8371 6089; www.futuremedicine.com

Future Medicine Ltd is part of the Future Science Group www.future-science-group.com
Errata/corrigenda.......................................................................................................................... 23
Duplicate publication/submission & plagiarism .................................................................................. 23
Scientific misconduct & retraction........................................................................................................ 24
Compliance with funder open or public access policies ....................................................................... 24
Manuscript deposition service for authors (NIH- and Wellcome Trust-funded articles) ............... 25
Self-archive policy .................................................................................................................................. 25
Author options post-publication ........................................................................................................... 27
Open access option ............................................................................................................................... 27
Access tokens .......................................................................................................................................... 28
Journal aims & scope

_Nanomedicine_ (ISSN 1743-5889) addresses the important challenges and advances in medical nanoscale-structured material and devices, biotechnology devices and molecular machine systems and nanorobotics, delivering this essential information in concise, clear and attractive article formats.

Coverage includes:

- Principles of nanomedicine, including basic research and theoretical applications
- Nanotechnological advances and their potential medical applications
- Disorders/conditions and the benefits of nanomedical tools versus traditional techniques
- Pre-clinical testing of novel nanomedical tools
- Diagnostic tools and applications
- Implanted nanodevices for the prevention and treatment of disease and the alleviation of pain
- Nanomedical tools in gene therapy for inherited diseases
- Tissue, cell and genetic engineering involving nanomedical tools
- Therapeutic applications of nanotechnology
- Drug delivery using nanoparticles (natural and artificial) or devices
- Technologies already in clinical use: diagnostics, therapeutics or surgical aids
- Prediction of adverse reactions of nanomedical technology, toxicology and safety issues
- Ethical, regulatory and legal issues
- Commercialization, funding and economics of nanomedical technology

The nanomedicine field is still in its infancy; however, in the next few years, there are likely to be further exciting developments across medical science, engineering, chemistry and physics. Diverse researchers working together under the nanomedicine umbrella will produce findings with potential medical uses: preventing, diagnosing and treating human diseases, as well as relieving pain. Nanomedicine will provide a critical overview of these advances as they unfold, helping to shape the future of medicine in this exciting era.

**Audience**

The audience for _Nanomedicine_ consists of research scientists and clinicians in the fields of chemistry, drug delivery, nanomedicine and nanotechnology. It is also of interest to decision-makers in the healthcare community as well as members of regulatory bodies. Authors should bear in mind the multidisciplinary status of the readership when writing the article.

_Nanomedicine_ articles have been engineered specifically for the time-constrained professional. The structure is designed to draw the reader’s attention directly to the information they require.
## At-a-glance article formatting checklist

<table>
<thead>
<tr>
<th></th>
<th>Word count range</th>
<th>Abstract</th>
<th>Keywords</th>
<th>Future Perspective</th>
<th>Executive Summary</th>
<th>Reference limit</th>
<th>Figures &amp; Tables permitted</th>
<th>Supporting cover letter required</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review</td>
<td>4000–6000</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>~80</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Perspective</td>
<td>4000–6000</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>~80</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Special Report</td>
<td>1500–3000</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>✔️</td>
<td>~50</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Full research article</td>
<td>4000–6000 (structured)</td>
<td>✔️</td>
<td>✔️</td>
<td>✗</td>
<td>✔️</td>
<td>~80</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Short Communication</td>
<td>3000–4000 (structured)</td>
<td>✔️</td>
<td>✔️</td>
<td>✗</td>
<td>✔️</td>
<td>~50</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Preliminary Communication</td>
<td>3000–4000 (structured)</td>
<td>✔️</td>
<td>✔️</td>
<td>✗</td>
<td>✔️</td>
<td>~50</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Methodology</td>
<td>3000–4000 (structured)</td>
<td>✔️</td>
<td>✔️</td>
<td>✗</td>
<td>✔️</td>
<td>~50</td>
<td>✔️</td>
<td>✔️</td>
</tr>
<tr>
<td>Editorial</td>
<td>1500</td>
<td>✗</td>
<td>✔️</td>
<td>✗</td>
<td>✗</td>
<td>20</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>Commentary</td>
<td>1500–3000</td>
<td>✗</td>
<td>✔️</td>
<td>✗</td>
<td>✗</td>
<td>20</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>Journal Watch</td>
<td>1500</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>20</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>Conference Report</td>
<td>1500</td>
<td>✔️</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>20</td>
<td>✗</td>
<td>✗</td>
</tr>
<tr>
<td>Company Profile</td>
<td>2000</td>
<td>✔️</td>
<td>✔️</td>
<td>✗</td>
<td>✔️</td>
<td>20</td>
<td>One of each max.</td>
<td>✗</td>
</tr>
<tr>
<td>Letter to the Editor</td>
<td>1500</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>✗</td>
<td>20</td>
<td>✗</td>
<td>✗</td>
</tr>
</tbody>
</table>
Article types

*Nanomedicine* publishes a range of article types, descriptions of which are outlined below. Authors are encouraged to consult the 'at-a-glance formatting checklist' for details on word counts and other formatting requirements.

The information below gives an overview of the requirements for each article type published by *Nanomedicine*. However, authors should consult the ICMJE “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” (http://www.icmje.org/icmje-recommendations.pdf), in particular the section on “Preparing a Manuscript for Submission to a Medical Journal” prior to submitting to *Nanomedicine*, for more detailed information.

Reviews

Reviews aim to highlight recent significant advances in research, ongoing challenges and unmet needs; authors should be concise and critical in their appraisal of the subject matter, and strive for clarity. The focus should be on key, defining developments rather than providing a comprehensive literature survey. Reviews should provide balanced coverage of the field and not focus predominantly on the author’s own research. Authors are encouraged to include their own perspective on current trends and future directions.

*Systematic Reviews:*

Systematic reviews should be conducted following the recommendations of PRISMA (http://www.prisma-statement.org/).

**Word limit:** 4000–6000 words (excluding abstract, executive summary, references and figure/table legends)

**Required sections** (for a more detailed description of these sections see Article sections):

- Title
- Author(s) names & affiliations
- Abstract
- Keywords
- Body of article
- Future perspective
- Executive summary
- References: target of approximately 80 references
- Reference annotations
- Financial disclosure/Acknowledgements

Perspectives

Perspectives have the same basic structure and length as review articles; however, they should be more speculative and forward-looking, even visionary. They offer the author the opportunity to present criticism, address controversy or provide a personal angle on a significant issue. Authors of perspectives are encouraged to be opinionated, with all positions concisely and clearly argued and referenced. Referees will be briefed to review these articles for quality and relevance of argument only. They will not necessarily be expected to agree with the author’s position.

**Word limit:** 4000–6000 words (excluding abstract, executive summary, references and figure/table legends)

**Required sections** (for a more detailed description of these sections see Article sections):

- Title
• Author(s) names & affiliations
• Abstract
• Keywords
• Body of article
• Future perspective
• Executive summary
• References: target of approximately 80 references
• Reference annotations
• Financial disclosure/Acknowledgements

Special Reports
Special reports are short review-style articles that highlight a particular niche area, be it a specific emerging field, novel hypotheses or method. Articles are categorized as Special Reports at the discretion of the Editorial team.

Word limit: 1500–3000 words (excluding abstract, executive summary, references and figure/table legends)

Required sections (for a more detailed description of these sections see Article sections):
• Title
• Author(s) names & affiliations
• Abstract
• Keywords
• Body of article
• Future perspective
• Executive summary
• References: target of approximately 50 references
• Reference annotations
• Financial disclosure/Acknowledgements

Original Research Articles
Authors of original research must provide a supporting Cover Letter on submission briefly detailing:
• Relevance to the journal’s audience
• Brief background and overview of the study
• Where the novelty in the study lies
• How the study advances understanding of the field
• Direct and potential implications of the findings
• In vitro studies must clearly state the translational potential of the findings

NB. Nanomedicine will consider studies presenting positive, negative or inconclusive data.

Authors are also advised to consult the Methods Reporting Checklist for Authors, available here.

Experimental details & data: Only where a novel experimental procedure has been employed full details must be provided, such that a skilled scientist would be able to reproduce the results presented. The synthesis of all new compounds must be described in detail. Details of routine or previously reported experimental procedures should be provided via references only. Experimental procedures and/or data running to more than two Word document pages should be placed in a supplementary information file.

Data sharing: If requested by the Editor or reviewers, authors should be able to provide additional relevant original data underpinning their research.

Future Medicine Ltd, Unitec House, 2 Albert Place, London, N3 1QB, UK; T: +44 (0)20 8371 6090; F: +44 (0)20 8371 6089; www.futuremedicine.com

Future Medicine Ltd is part of the Future Science Group www.future-science-group.com
Clinical Trial reporting: For authors presenting the results of clinical trials, the guidelines recommended by CONSORT (http://www.consort-statement.org/) and GPP3 (http://www.ismpp.org/gpp3) should be followed. In addition, where available the clinical trial registration number should be included at the end of the abstract, and on the first mention of the trial in the main body of text. Unregistered clinical trials should be declared as such, and the reason for nonregistration should be provided. Mention of other trials should also include the relevant registration number, where available.

Secondary outcomes, exploratory analyses, and post hoc analyses should be clearly identified as such; these may be included in the primary publication or published separately, in which case they should clearly reference the primary publication and should not be published before it.

Observational studies: Where observational research has been carried out, authors should follow the recommendations of STROBE (http://www.strobe-statement.org/).

Data deposition: Where data have been deposited in a public repository, authors should state at the end of the abstract the data set name, repository name and number.

Word and figure/table limit: Limits vary depending on journal title. Please contact the relevant Commissioning Editor for further details.

Required sections (for a more detailed description of these sections see Article sections):

- Title
- Author(s) names & affiliations
- Structured abstract
- Keywords
- Introduction
  - Should only cite directly pertinent references
  - Should not include data of conclusions from the work being reported
- Patients & methods/Materials & methods
  - Where an organization was paid or otherwise contracted to help conduct the research (e.g., data collection and management), this should be detailed
  - Should include information indicating that the research was approved or exempted from the need for review by the responsible review committee (institutional or national). Where no formal ethics committee is available, a statement indicating that the research was conducted according to the principles of the Declaration of Helsinki should be included
  - Information on the selection and description of participants should define how authors measured race or ethnicity and justify their relevance
- Results
  - Numeric results should be given not only as derivatives (e.g., percentages) but also as the absolute numbers from which the derivatives were calculated
  - Statistical significance of results should be specified, if any
- Discussion
  - Authors should distinguish between clinical and statistical significance, and avoid making statements on economic benefits and costs unless the manuscript includes the appropriate economic data and analyses
  - Authors should avoid claiming priority or alluding to work that has not been completed
- Conclusions
Four types of research article are accepted:

**Full research article (Word limit: 4000–6000 words)**
Research articles should present novel work that makes a significant impact within the scope of the journal, and which represents an important advancement in knowledge or understanding. Routine or incremental work is not suitable for full research papers. Research should be reported succinctly; the inclusion of detailed background discussion is to be avoided. Supporting data or further experimental details can be submitted as Supplementary Information.

**Preliminary communication (Word limit: 3000–4000 words)**
Preliminary communication articles are intended for short reports of studies that present promising improvements or developments on existing areas of research. The significance and potential implications of the developments must be explicit.

**Short communication (Word limit: 3000–4000 words)**
Short communication articles are short, peer-reviewed articles that build on a previously published study, document partial research results from an ongoing study, or discuss results from studies limited in scope.

**Methodology (Word limit: 3000–4000 words)**
Methodology articles should provide an overview of a new experimental or computational method, test or procedure. The method described may be either completely novel, or may offer a demonstrable improvement on an existing method. The significance and potential implications of the developments must be explicit.

**Editorials**
Editorials are short articles that provide an insight into, or snapshot of issues of topical importance to the journal’s target audience or researchers and other professionals. The intention is that the article should offer an expert perspective on a topic of recent interest. More detailed discussions can take the form of Commentary articles.

**Word limit:** 1500 words maximum (excluding keywords and references).

**Required sections** (for a more detailed description of these sections see Article sections):
- Title
- Author(s) names & affiliations
- Photo (headshot) of authors (including up to one co-author if desired)
- Keywords
- Body of article
- References: Please note: A maximum of 20 references are permitted
- Financial disclosure/Acknowledgements
- Please note: No figures, tables or boxes are permitted in editorials
Commentaries
Commentaries are short articles that are similar to Editorials, yet provide a more detailed discussion of a topic.

Word limit: 1500–3000 words (excluding keywords and references).
Required sections (for a more detailed description of these sections see Article sections):
- Title
- Author(s) names & affiliations
- Photo (headshot) of authors (including co-authors if desired)
- Keywords
- Body of article
- References: Please note: A maximum of 20 references are permitted
- Financial disclosure/Acknowledgements
- Please note: No figures, tables or boxes are permitted in commentaries

Interviews
Interviews are conducted with key opinion leaders in the field, and can include a look back over their career and achievements to date, a discussion on their current research, and their thoughts and observations on the field as a whole.

Word limit: 1500 words
Required sections:
- Title
- Interviewee name & affiliation
- Photo (headshot) of the interviewee
- Summary/biographical paragraph
- Series of questions for discussion (provided by the journal’s Commissioning Editor)
- Response from the author to each point
- Additional reference sources for the interested reader

Journal Watch
Journal Watch discusses a number of recent original research papers, summarizing and commenting on each paper to give readers a real sense of the cutting edge of research in the field.

Word limit: 3–4 brief summaries on recent research of 200–500 words each (excluding references).
Required sections:
- Citation of original research paper
- Summary paragraph
- References: Please note: A maximum of 20 references are permitted
- Financial disclosure/Acknowledgements
- Please note: No figures, tables or boxes are permitted in research highlights

Conference Reports
Conference scenes aim to summarize the most important research presented at a recent relevant meeting or event. It is not usually feasible to attempt comprehensive coverage of the conference; authors should therefore focus on those presentations that are most topical, interesting or thought-provoking.

Word limit: 1500 words maximum (excluding abstract, conference details and references).
Required sections:
Future Medicine Ltd, Unitec House, 2 Albert Place, London, N3 1QB, UK; T: +44 (0)20 8371 6090; F: +44 (0)20 8371 6089; www.futuremedicine.com

Future Medicine Ltd is part of the Future Science Group www.future-science-group.com
• Conference details (title, date, location)
• Abstract/overview of meeting (120 words maximum)
• Body of article
• References: Please note: A maximum of 20 references are permitted
• Financial disclosure/Acknowledgements
• Please note: No figures, tables or boxes are permitted in conference scenes

Company Profiles
Company profiles allow representatives from pharmaceutical, biotechnology, etc. companies to describe the work currently being carried out within their particular organization, relevant to the field of the journal in question.

These reports are intended to provide an insight into the history and strategy of a company and profile its corporate capabilities, advanced technologies and future potential.

Word limit: 2000 words
Required sections (for a more detailed description of these sections see Article sections):
• Title
• Author(s) names & affiliations
• Abstract
• Keywords
• Introduction – brief factual account of the history and strategy of the company including background information e.g., the year the company was founded, number of employees etc.
• Body of article
• Summary points
• Financial disclosure/Acknowledgements
• Please note: A maximum of 20 references are permitted
• Figures/tables: if necessary, only one of each is permitted

Letters to the Editor
Readers may submit Letters to the Editor, commenting on an article published in the journal.

Word limit: 1500 words

Inclusion of Letters to the Editor in the journal is at the discretion of the Editor. All Letters to the Editor will be sent to the author of the original article, who will have 28 days to provide a response to be published alongside the Letter.

Drug, Device & Vaccine Evaluations
Separate author guidelines for the submission of these article types are available. Please contact the Drug Evaluations Commissioning Editor to request a copy.

Clinical Trial Protocols & Clinical Trial Evaluations
Separate author guidelines for the submission of these article types are available. Please contact the Drug Evaluations Commissioning Editor to request a copy.
Article sections
The following list provides notes on the key article sections; authors should consult the ‘at-a-glance formatting checklist’ to determine which sections are required for their submission.

Title
Concisely and clearly conveys the scope/novelty of the article; not more than 120 characters.

Author(s) names & affiliations
Including full name, address and e-mail.

Guidance on author sequence:
Author sequence is at the authors’ discretion; however, Nanomedicine suggests following the recommendations in GPP3 Appendix Table 2 (http://www.ismpp.org/gpp3), whereby authors are listed either in order of the level of their contribution, or alphabetically. The corresponding author should always be indicated.

Guidance on a change of affiliation during writing:
Where an author has changed their affiliation prior to the publication of an article, the affiliation should reflect where the major part of the work was completed. Current affiliation and contact information should be listed in an acknowledgement.

Abstract
Not more than 120 words; no references should be cited in the abstract. The abstract should highlight the importance of the field under discussion within the journal’s scope, and clearly define the parameters of the article.

Structured abstract (for Research articles)
Not more than 120 words, broken down into Aims, Patients & Methods/Materials & Methods, Results and Conclusions. For authors presenting the results of clinical trials, the guidelines recommended by CONSORT should be followed when writing the abstract (http://www.consort-statement.org/), and the clinical trial registration number included at the end of the abstract, where available.

Data deposition: where data have been deposited in a public repository, authors should state at the end of the abstract the data set name, repository name and number.

Keywords
Up to 10 keywords (including therapeutic area, mechanism[s] of action etc.) plus names of drugs and compounds mentioned in the text.

Body of the article
The article content should be arranged under relevant headings and subheadings to assist the reader.

Future perspective
The author is challenged to include speculative viewpoint on how the field will have evolved 5–10 years from the point at which the article was written.

Executive summary
A series of bulleted summary points that illustrate the main topics or conclusions made under each of the main headings of the article.
Example:

<table>
<thead>
<tr>
<th>cutaneous nevi</th>
<th>NN-1 Gag reaches the site of assembly via specific vesicular trafficking pathways</th>
</tr>
</thead>
<tbody>
<tr>
<td>NN-1 Gag directs the assembly process and forms the core of the viral particle. Gag moves to the site of assembly, classically the plasma membrane, through a series of interactions with components of the vesicular transport pathways.</td>
<td></td>
</tr>
</tbody>
</table>

**Financial disclosure/Acknowledgements**

Disclosing any financial and/or material support that was received for the research or the creation of the work. Also disclosing any relationships any authors have (personal, academic or financial relationships that could influence their actions) or financial involvement with an organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. If writing assistance has been used in the creation of the manuscript, this should also be stated and any sources of funding for such assistance clearly identified.

**Ethical conduct of research**

For studies involving data relating to human or animal experimental investigations, authors should obtain appropriate institutional review board approval and state this within the article (for those investigators who do not have formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed). In addition, for investigations involving human subjects, authors should obtain informed consent from the participants involved and include an explanation of how this was obtained in the manuscript.
References

Key points

- Authors should focus on recent papers and papers older than 5 years should not be included except for an over-riding purpose.
- Primary literature references, and any patents or websites, should be numerically listed in the reference section in the order that they occur in the text (including any references that only appear in figures/tables/boxes).
- Information from manuscripts submitted but not accepted should be cited in the text as “unpublished observations” with written permission from the source.
- Avoid citing a “personal communication” unless it provides essential information not available from a public source, in which case the name of the person and date of communication should be cited in the text, with written permission from the source.
- References should be denoted numerically and in sequence in the text, using Arabic numerals placed in square brackets, i.e., [12].
- Quote first six authors’ names. If there are more than six, then quote first three et al.
- Reference annotations: 6–8 references should be highlighted that are of particular significance to the subject under review as “* of interest” or “** of considerable interest”, along with a brief (1–2 line) synopsis.
- The Future Medicine Reference Manager and EndNote styles can be downloaded from our website at: www.futuremedicine.com/page/authors.jsp

Format

- Author’s names should appear without full stops in their initials
- Quote first six authors’ names. If there are more than six, then quote first three et al.
- A full stop follows authors’ names
- Journal name should be in italics and abbreviated to standard format
- Volume number followed by comma, not bold
- Page number range separated by a hyphen with no spaces, followed by the year in brackets, and then a full stop

Examples

Journal example:

Book example:

Meeting abstract example:

Patent example:

**Website example (organization homepage):**
US Food and Drug Association.
www.fda.gov

**Website example (specific webpage/document):**
www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/index

www.hcup-us.ahrq.gov/reports/statbriefs/sb30.pdf

**Reference annotations**
Papers or of particular interest should be identified using one or two asterisk symbols:

- * = of interest
- ** = of considerable interest

Each of the chosen references should be annotated with a brief sentence explaining why the reference is considered to be of interest/particular interest.
Figures, tables & boxes

Summary figures, tables and boxes are very useful, and we encourage their use in certain article types (see above section on Article types for details on which articles can include figures/tables/boxes). The author should include illustrations to condense and illustrate the information they wish to convey. Commentary that augments an article and could be viewed as ‘stand-alone’ should be included in a separate box. An example would be a summary of a particular trial or trial series, a case study summary or a series of terms explained.

Figures, tables and boxes should be numbered consecutively according to the order in which they have been first cited in the text. All abbreviations used within them should be defined in the legend.

All figures, tables and boxes should be submitted in an editable format. Ideally these should be sent as Microsoft Word, Microsoft Excel or Adobe Illustrator files. If you are uncertain whether the format of your files is appropriate, please check with the Commissioning Editor. It is unnecessary to incorporate copies into the body of the manuscript; however, they should be included at the end of the document where possible.

Please ensure that scale bars are included in figures where appropriate (i.e., photomicrographs). Symbols, arrows or letters used in photomicrographs should contrast with the background. Please explain internal scale and identify the method of staining in photomicrographs.

If any of the figures, tables or boxes used in the manuscript requires permission from the original publisher, it is the author’s responsibility to obtain this. More details on obtaining permissions can be found in the copyright section below.

Please note, Nanomedicine does not accept Schemes. Please incorporate Schemes as Figures.

Supplementary information

Figure, tables and boxes larger than one A4 page will be included as online-only supplementary information. At the Editor’s discretion data or experimental details can also be included.

Color figure charge

Nanomedicine has a charge for the printing of color figures (i.e., each color page) in the print issue of the journal. We have no page charges, unlike some other publishers, and aim to keep our color charge to a minimum.

This charge does not apply to the online (including PDF) version of articles, where all figures appear in color at no charge.

Chemical structures

If possible, please submit structures drawn in ISISDraw or Chemdraw format. However, chemical structures can be redrawn in-house. Please use the following conventions:

- Always indicate stereochemistry where necessary – use the wedge and hash bond convention for chiral centers and mark cis/trans bonds as such.
- Draw small peptides (up to five amino acids) in full; use amino acid abbreviations (Gly, Val, Leu, etc.) for larger peptides.

Future Medicine Ltd, Unitec House, 2 Albert Place, London, N3 1QB, UK; T: +44 (0)20 8371 6090; F: +44 (0)20 8371 6089; www.futuremedicine.com

Future Medicine Ltd is part of the Future Science Group www.future-science-group.com
• Refer to each structure with a number in the text; submit a separate file (i.e., not pasted throughout the text) containing these numbered structures in the original chemical drawing package that you used.

**Electronic files**

Please submit any other illustrations in an editable electronic format such as Illustrator, PowerPoint, Excel or as postscripted/encapsulated postscripted (.ps/.eps) files.

Photos should be provided at a resolution of 600 dpi, or as high as possible.

**Permissions for reproduced or adapted material within your article**

If a figure, table or box has been published previously (even if you were the author), acknowledge the original source and submit written permission from the copyright holder to reproduce the material where necessary.

As the author of your manuscript, you are responsible for obtaining permissions to use material owned by others. Since the permission-seeking process can be remarkably time-consuming, it is wise to begin writing for permission as soon as possible.

Future Medicine is a signatory to the STM Permissions Guidelines produced by the International Association of Scientific, Medical and Technical Publishers (http://www.stm-assoc.org/). Permission is, or in the case of an express permission requirement should be, granted free of charge by signatory organizations, with respect to a particular journal article or book being prepared for publication, to:

• Use up to three figures (including tables) from a journal article or book chapter, but:
  o not more than five figures from a whole book or journal issue/edition;
  o not more than six figures from an annual journal volume; and
  o not more than three figures from works published by a single publisher for an article, and not more than three figures from works published by a single publisher for a book chapter (and in total not more than thirty figures from a single publisher for re-publication in a book, including a multi-volume book with different authors per chapter).

• Use single text extracts of less than 400 words from a journal article or book chapter, but not more than a total of 800 words from a whole book or journal issue/edition.

Permission to go beyond such limits may be sought although in such instances the permission grant may require permission fees. **Important** – although permission may be granted without charge, authors must ensure that appropriate permission has nevertheless been obtained. Co-signatories of the permissions agreement can be found on the following website: http://www.stm-assoc.org/copyright-legal-affairs/permissions/permissions-guidelines/.

Please send us photocopies of letters or forms granting you permission for the use of copyrighted material so that we can see that any special requirements with regard to wording and placement of credits are fulfilled. Keep the originals for your files. If payment is required for use of the figure, this should be covered by the author.
**Units of measurement**

Measurements of length, height, weight and volume should be reported in metric units (meter, kilogram or liter) or their decimal multiples.

Temperatures should be in degrees Celsius.

Blood pressures should be in millimeters of mercury.

Any other units should be reported using the International System of Units (SI) where possible.

**Statistics**

Describe statistical methods with enough detail to enable a knowledgeable reader with access to the original data to judge its appropriateness for the study and to verify the reported results.

When possible, appropriate indicators of measurement error or uncertainty (such as confidence intervals) should be included.

Please define any statistical terms, abbreviations and symbols used.
Pre-submission editing services

*Nanomedicine* partners with Enago to provide pre-submission editing services for our authors.

Editing services include:

- Language check
- Copyediting
- Substantive editing

For more information, please visit the website here: [http://futuremedicine.enago.com](http://futuremedicine.enago.com)
Submission

Please ensure that solicited manuscripts are submitted on or before the agreed deadline. If a manuscript requires authorization by your organization before submission, please remember to take this into account when working towards these deadlines.

First draft submission should be made via our online submission portal in the first instance. Guidelines to using the system can also be found on this page. If possible, manuscripts should be submitted in MS Word v. 6–8 format. However, we can convert most word-processing packages.

To help with the speed of processing of an article, authors should ensure that their article has been edited for language and grammar by a fluent English speaker prior to submission.

Peer review

Once the manuscript has been received in-house, it will be peer-reviewed (this usually takes around 4 weeks). Please provide a list of suitable peer reviewers with your initial submission.

Revision

After peer review is complete, a further 2 weeks is allowed for any revisions (suggested by the referees/Editor) to be made.

In-house production

Once a revised manuscript has been accepted for publication, it will undergo production in-house. This will involve type-setting, copy-editing, proof-reading and re-drawing of any graphics. Authors will receive proofs of the article to approve before going to print, and will be asked to sign a copyright transfer form (except in cases where this is not possible, i.e., government employees in some countries).

Please note that once the author receives the copy of their article for approval, our production department will need to hear from them within a tight deadline to ensure the issue is published on schedule. If you believe you may be away and unable to check the galley proofs at any point, please let the Commissioning Editor know.

Accelerated publication option

Our fee-based accelerated publication option provides publication of accepted articles online ahead of the print issues, within 6 weeks of submission (subject to receiving a signed Accelerated Publication Agreement form on the day of submission, and acceptance following peer-review and article revisions). If you are interested in this option, please inform the relevant Editor once they have confirmed receipt of your first draft.

The Accelerated publication fee for Nanomedicine is £190 per published page, plus VAT where applicable. Discounts are available for authors choosing both the Open Access and Accelerated Publication options.
Editorial policies

_Nanomedicine_ endorses the **Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals**, issued by the International Committee for Medical Journal Editors, the **Code of Conduct and Best Practice Guidelines for Journal Editors**, produced by the Committee on Publication Ethics, and **GPP3** (http://www.ismpp.org/gpp3). This information is also available at [www.futuremedicine.com](http://www.futuremedicine.com).

Manuscript submission & processing

_Nanomedicine_ publishes a range of article types, including solicited and unsolicited reviews, perspectives and original research articles. Receipt of all manuscripts will be acknowledged within 1 week and authors will be notified as to whether the article is to progress to external review. Initial screening of articles by internal editorial staff will assess the topicality and importance of the subject, the clarity of presentation, and relevance to the audience of the journal in question.

If you are interested in submitting an article, or have any queries regarding article submission, please contact the Commissioning Editor for the journal, via the [Editorial Director](#). For new article proposals, the Commissioning Editor will require a brief article outline and working title in the first instance. We also have an active commissioning program whereby the Commissioning Editor, under the advice of the Editorial Board, solicits articles directly for publication.

External peer review

Through a rigorous peer review process, _Nanomedicine_ aims to ensure that articles are unbiased, scientifically accurate and clinically relevant. All articles are peer reviewed by three or more members of the International Editorial Board or other specialists selected on the basis of experience and expertise. Review is performed on a double-blind basis – the identities of peer reviewers and authors are kept confidential. Peer reviewers must disclose potential conflicts of interests that may affect their ability to provide an unbiased appraisal (see Conflict of Interest Policy below). Peer reviewers complete a referee report form, to provide general comments to the editor and both general and specific comments to the author(s).

Where an author believes that an editor has made an error in declining a paper, they may submit an appeal. The appeal letter should clearly state the reasons why the author(s) considers the decision to be incorrect and provide detailed, specific responses to any comments relating to the rejection of the article. Further advice from members of the journal’s Editorial Board and/or other external experts will be sought regarding eligibility for re-review.

Revision

Most manuscripts require some degree of revision prior to acceptance. Authors should provide two copies of the revised manuscript – one of which should be highlighted to show where changes have been made. Detailed responses to reviewers’ comments are also required (authors should complete these sections in the supplied Peer Review Report Form). Manuscripts may be accepted at this point or may be subject to further peer review. The final decision on acceptability for publication lies with the journal editor.

Post-acceptance

Accepted manuscripts will undergo production in-house. This will involve type-setting, copy-editing, proof-reading and re-drawing of any graphics. Authors will receive proofs of their article for approval and sign off and will be asked to sign a transfer of copyright agreement, except in circumstances where the author is ineligible to do so (e.g. government employees in some countries).
Please note that once the author receives the copy of their article for approval, our production department will need to hear from them within a tight deadline to ensure the issue is published on schedule. If you believe you may be away and unable to check the galley proofs at any point, please let the Commissioning Editor know.

**Embargo policy**

- Following the acceptance of articles for publication, authors (and their institutions, etc.) are welcome to publicize the publication; authors wishing to do so, should advise the editor of the details beforehand.
- No publicity relating to publication in *Nanomedicine* should be carried out while the manuscript is under consideration. However, prior publicity linked to presentations at meetings does not jeopardize publication in *Nanomedicine*.
- In cases where data may be of overwhelming public health importance, the above policy may be waived; should this be the case, the appropriate authorities responsible for public health should decide whether to disseminate information to physicians and the media in advance and should be responsible for this decision. The journal editor should be informed if these circumstances apply.

Any queries relating to publicity of manuscripts should be directed to the journal editor.

**Disclosure & conflict of interest policy**

Authors must state explicitly whether financial and/or nonfinancial relationships exist that potentially conflict with the subject matter or materials discussed in the manuscript and any such potential conflict of interest (including sources of funding) should be summarized in a separate section of the published article. Authors must disclose whether they have received writing assistance and identify the sources of funding for such assistance. Authors declaring no conflict of interest are required to publish a statement to that effect within the article.

Authors must certify that they have disclosed relationships in which they (or a close family member): is employed, is a contractor, provides services, or has otherwise collaborated in commercial or scientific pursuits – even in the absence of direct monetary remuneration. Stock holdings and issued or pending patents of an author or family member should also be disclosed. This list is not exclusive of other forms of financial involvement. A 36-month disclosure window should be used. Details of relevant conflicts of interests (or the lack of) must be declared in the ‘Disclosure’ section of the manuscript for all listed authors.

External peer reviewers must disclose any conflicts of interest that could bias their opinions of the manuscript, and they should disqualify themselves from reviewing specific manuscripts if they believe it appropriate. Should any such conflict of interest be declared, the journal editor will judge whether the reviewer’s comments should be recognized or will interpret the reviewer’s comments in the context of any such declaration.

**Ethical conduct of research**

For studies involving data relating to human or animal experimental investigations, appropriate institutional review board approval is required and should be described within the article. For those investigators who do not have formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed. For investigations involving human subjects, authors should explain how informed consent was obtained from the participants involved.
**Patients’ rights to privacy**
Patients have a right to privacy that should not be infringed without informed consent. Identifying information should not be included unless the information is essential for scientific purposes and the patient (or parent or legal guardian) gives written informed consent for publication. Informed consent for this purpose requires that the patient be shown the manuscript to be published. When informed consent has been obtained it should be indicated in the manuscript.

In attempting to maintain patient anonymity, identifying details should be omitted where they are not essential. However, patient data should never be amended or falsified. Informed consent should be obtained whenever there is any doubt that anonymity can be assured.

**Use of personal communications & unpublished data**
Where an individual is identified within an article as a source of information in a personal communication or as a source for unpublished data, authors should include a signed statement of permission from the individual(s) concerned and specify the date of communication.

**Clinical trial registration**
Future Medicine titles prefer to publish clinical trials that have been included in a clinical trials registry that is accessible to the public at no charge, is electronically searchable, is open to prospective registrants and is managed by a not-for-profit organization, such as [www.clinicaltrials.gov](http://www.clinicaltrials.gov) (sponsored by the United States National Library of Medicine). Where a clinical trial registration number is available, this should be included at the end of the abstract and also listed the first time the authors use a trial acronym to refer to the trial they are reporting in the manuscript. Unregistered clinical trials should be declared as such, and the reason for nonregistration should be provided.

Whilst referees will take registration status into account, all well designed and presented trials and corresponding data will be considered for publication.

**Errata/corrigenda**
Mistakes by either editor or author should be identified wherever possible and an erratum or corrigendum published at the earliest opportunity. We will attempt to contact the author of the original article to confirm any error, and publish an appropriate erratum or corrigendum at the earliest opportunity.

**Duplicate publication/submission & plagiarism**
All manuscripts submitted to *Nanomedicine* are considered for publication on the understanding that they have not been published previously elsewhere or are under consideration for publication elsewhere. The journal may, however, consider republication of a paper previously published in a language other than English, subject to prominent disclosure of the original source and with any necessary permission. Authors will be asked to certify that the manuscript represents valid work and that neither this manuscript nor one with substantially similar content under their authorship has been published or is being considered for publication elsewhere.

Where specific findings from a particular study have been previously published (in Future Medicine titles or elsewhere), *Nanomedicine* will not consider manuscripts reporting the same findings, except where:
- the results are substantially reanalyzed, reinterpreted for a different audience, or translated into another language;
- the primary publication is clearly acknowledged and cited and the trial registration number (where available) of the original research is included; and
• the publication is clearly presented as an analysis derived from the primary publication results or marked as a translation, with appropriate permission obtained from the previous publisher and copyright laws upheld.

All submitted articles will be evaluated using plagiarism detection software, which compares the submitted manuscript with full text articles from all major journal databases and the internet.

The use of published or unpublished ideas, words or other intellectual property derived from other sources without attribution or permission, and representation of such as those of the author(s) is regarded as scientific misconduct and will be addressed as such.

**Scientific misconduct & retraction**
If misconduct by authors or reviewers is suspected, either pre- or post-publication, action will be taken. An explanation will be sought from the party or parties considered to be involved. If the response is unsatisfactory, then an appropriate authority will be asked to investigate fully. *Nanomedicine* will make all reasonable attempts to obtain a resolution in any such eventuality and correct the record or archive as necessary (publishing a retraction of the article as required).

**Compliance with funder open or public access policies**
*Nanomedicine* is supportive of open and public access policies mandated by various funding bodies (see list below). In the first instance, please check whether your article type is covered by your funder mandate (i.e., in some cases, funder policies only cover research articles, rather than review articles). Please advise the Editor on submission if your article was funded by any of the bodies below.

Where open access publication is a requirement of your funding, our article processing charge will need to be paid (in many cases, this will be covered by your funder, and you should check the specific details of this on the funder website). Please see further information below on our Open Access Option for authors.

As standard for our Open Access option, articles are published under a CC BY-NC-ND license, and this will be used in the first instance; however, where the funder requires it, articles can be published under a difference Creative Commons license (i.e., the CC BY license in the case of The Wellcome Trust).

**Funding bodies:**
Action on Hearing
Arthritis Research UK
Association for International Cancer Research (AICR)
Austrian Science Fund (FWF)
Biotechnology and Biological Sciences Research Council (BBSRC)
Breakthrough Breast Cancer
Breast Cancer Campaign
British Heart Foundation (BHF)
Canadian Institutes of Health
Cancer Research UK (CRUK)
Chief Scientist Office (Scotland)
Diabetes UK
Dunhill Medical Trust
European Research Council (ERC)
Howard Hughes Medical Institutes (HHMI)

*Future Medicine Ltd*, Unitec House, 2 Albert Place, London, N3 1QB, UK; T: +44 (0)20 8371 6090; F: +44 (0)20 8371 6089; [www.futuremedicine.com](http://www.futuremedicine.com)

Future Medicine Ltd is part of the Future Science Group [www.future-science-group.com](http://www.future-science-group.com)
Marie Curie Cancer Care
Medical Research Council (MRC)
Motor Neuron Disease Association
Multiple Sclerosis Society
Myelovlytis Trust
National Institute for Health Research (Department of Health)
National Institutes of Health (NIH)
Parkinson's UK
Prostate Cancer UK
Telethon Italy
The Wellcome Trust
Yorkshire Cancer Research

NB. The above list of funders may not be exhaustive; should you have requirements related to a funder that is not listed above, please contact the Editorial Director discuss further.

Manuscript deposition service for authors (NIH- and Wellcome Trust-funded articles)
To assist our NIH- and Wellcome Trust-supported authors in meeting the requirement to deposit their article with PubMed Central (NIH) and Europe PMC (Wellcome Trust), Nanomedicine will deposit the final published PDF of the article on their behalf, within 2 weeks of online publication. Authors will then be contacted to provide the final information to complete the process (i.e., funding source).

In the case of NIH-funded authors, articles will be freely accessible via PubMed Central and searchable within its index no later than 12 months after publication. Wellcome Trust-funded articles will be deposited with Europe PMC and made open access under a Creative Commons CC BY license upon publication (subject to receipt of the article processing charge). Wellcome Trust-funded authors are required to complete a separate license form and payment form.

If you require further assistance or have any questions, please contact the Editorial Director to discuss further.

Self-archive policy
Future Medicine is supportive of self-archiving. Should you be interested in archiving your work, please be aware of the policies below.

Definition of article versions:
- **Submitted version** – authors’ version of the article that has been submitted to the journal and entered into the peer review process (no revisions have yet been made)
- **Authors’ final version** – authors’ version of the article that has been through the peer review process, revised accordingly, and accepted for publication by the journal.
- **Version of record** – Future Medicine’s version of the article that has been accepted for publication and typeset into the final journal format (including copyediting, formatting, redrawing of illustrations, etc.).

The Future Medicine self-archiving policies differ depending on the final copyright status of your article. Authors should adopt the self-archiving policy corresponding to the publishing route that they have opted for. The first section sets out the policy applicable for instances where copyright is assigned to the publisher. The subsequent section explains the rights applicable where an author has chosen the open access option.

**Future Medicine Ltd**, Unitec House, 2 Albert Place, London, N3 1QB, UK; T: +44 (0)20 8371 6090; F: +44 (0)20 8371 6089; www.futuremedicine.com

Future Medicine Ltd is part of the Future Science Group www.future-science-group.com
Where copyright is assigned to the publisher (standard publication option requiring no article processing charge)
The rights outlined here apply in circumstances where copyright has been assigned to the publisher.

a) Submitted version
Authors may:
- Share print or electronic copies of the article with colleagues. In doing so, they should state that the article has been submitted for publication to [the specified journal].
- Post an electronic version of an article on a personal website, the website of an employer or institution, or to free public servers.

b) Authors’ final version
Authors may:
- Share print or electronic copies of the article with colleagues.
- 3 months after publication – post the Authors’ final version on a personal website.
  - Subject to appropriate acknowledgment of the journal and full bibliographic reference to the article.
- 12 months after publication – post the Authors’ final version on their employer’s website or on free public servers in their subject area.
  - Subject to appropriate acknowledgment of the journal and full bibliographic reference to the article.

c) Version of record
Requests for posting of the version of record on any website within any timeframe should be directed to Future Medicine via our Permissions Requests page.

Should the author wish to do any of the above within a shorter timeframe than specified, requests should be directed to Future Medicine via our Permissions Requests page.

Please see our Permissions Requests page for information on the rights authors retain to re-use parts of their article in future works. Authors cannot reproduce an article for commercial purposes (i.e., for monetary gain on their own account or on that of a third party, or for indirect financial gain by a commercial entity). However, this does not affect an author’s rights to receive a royalty or other payment for works of scholarship.

Articles published via the open access option (article processing fee applies)
The rights outlined below apply specifically to all articles published via the open access option route.

Using the standard Nanomedicine open access option, articles are published under a Creative Commons CC BY-NC-ND license, which allows dissemination on an open access basis, but does not permit commercial exploitation or the creation of derivative works without permission (for further details from www.creativecommons.org). Please see our Permissions Requests page to request permissions in these circumstances.

Provided that authors give appropriate acknowledgment to the journal and publisher, and cite the full bibliographic reference for the article, when it is published open access (i.e., when the article processing fee has been received), authors may:
- Share print or electronic copies of an article with colleagues
• Post the version of record on:
  o Personal websites
  o An employer’s website
  o Free public servers in their subject area
• Use all or part an article and abstract in personal compilations or other scholarly publications of their own work (and may receive a royalty or other payment for such work)
• Use an article within their employer’s institution or company for educational or research purposes, including use in course packs

Electronic versions of an accepted article should include a link to the published version of the article together with the following: ‘For full bibliographic citation, please refer to the version available at www.futuremedicine.com’.

Third parties are entitled to use an article published via the open access option route, in whole or in part, in accordance with the conditions outlined in the CC BY-NC-ND license (see information above).

Author options post-publication

Open access option
Authors who wish to publish in any Future Medicine title can opt for our Open Access Option, allowing unrestricted access to the online version of their article. The Open Access Option is available for all article types except Drug, Device and Vaccine Evaluation articles.

Authors of accepted peer-reviewed articles may choose to pay a fee in order for their published article to be made accessible on an open access basis at www.futuremedicine.com and flagged as such on the website. Using this option, articles are published under a Creative Commons CC BY-NC-ND license, which allows dissemination on an open access basis, but does not permit commercial exploitation or the creation of derivative works without permission (for further details from www.creativecommons.org). Please see our Permissions Requests page to request permissions in these circumstances.

The Open Access Option fee is as follows:

<table>
<thead>
<tr>
<th>Article Type</th>
<th>Open access fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Review</td>
<td>£1,785*</td>
</tr>
<tr>
<td>• Perspective</td>
<td></td>
</tr>
<tr>
<td>• Special Report</td>
<td></td>
</tr>
<tr>
<td>• Full Research Article</td>
<td></td>
</tr>
<tr>
<td>• Preliminary Communication</td>
<td></td>
</tr>
<tr>
<td>• Short Communication</td>
<td></td>
</tr>
<tr>
<td>• Methodology</td>
<td></td>
</tr>
<tr>
<td>• Editorial</td>
<td>£610*</td>
</tr>
<tr>
<td>• Commentary</td>
<td></td>
</tr>
<tr>
<td>• Journal Watch</td>
<td></td>
</tr>
<tr>
<td>• Conference Report</td>
<td></td>
</tr>
<tr>
<td>• Company Profile</td>
<td></td>
</tr>
<tr>
<td>• Letter to the Editor</td>
<td></td>
</tr>
</tbody>
</table>

*Plus VAT where applicable

Future Medicine Ltd, Unitec House, 2 Albert Place, London, N3 1QB, UK; T: +44 (0)20 8371 6090; F: +44 (0)20 8371 6089; www.futuremedicine.com

Future Medicine Ltd is part of the Future Science Group www.future-science-group.com
Authors are required to complete a license and payment form (available from our website). The publication fee is charged on acceptance of the article and payment in full should be paid within 30 days (preferably by credit card) by the author or other funding body. Authors not paying by credit card may request to be invoiced in US Dollars or Euros at the prevailing equivalent rate (using www.xe.com). The source of funding for open access fees should be included in the Financial & Competing Interests Disclosure statement.

Please note that the fee must be received before the article is made open access.

All articles are subject to our standard peer-review process and will be accepted or rejected based on their own merit.

*Use by commercial 'for-profit' organizations*

Use of Open Access Option articles for commercial purposes is not permitted. However, support for free access is available to third parties subject to the appropriate permission fees (contact: reprints@futuremedicine.com).

Commercial purposes include:

- Copying or downloading of articles, or linking to such articles for further redistribution, sale or licensing
- Copying, downloading or posting by a site or service that incorporates advertising with such content
- The inclusion or incorporation of article content in other works or services (other than normal quotations with an appropriate citation) that is then available for sale or licensing, for a fee (for example, a compilation produced for marketing purposes, inclusion in a sales pack)
- Use of article content (other than normal quotations with appropriate citation) by for-profit organizations for promotional purposes
- Linking to article content in e-mails redistributed for promotional, marketing or educational purposes
- Use for the purposes of monetary reward by means of sale, resale, license, loan, transfer or other form of commercial exploitation such as marketing products.

Print reprints of Open Access Option articles can be purchased from reprints@futuremedicine.com.

If you have a query regarding our Open Access Option please contact Francesca Lake, Managing Editor – Open Access.

**Access tokens**

*What is an access token?*

An access token allows a single user to access a certain amount of content an indefinite number of times. Most commonly, this is a single article – but can be any set of content, up to and including access to all of our content. Please note that access tokens are only available to authors for non-commercial purposes. For authors or third parties wishing to host an article on a company website, please contact reprints@futuremedicine.com.

*Why use an access token?*

An access token offers a cost-effective and time-efficient way of offering access to a targeted group of people. It allows an author to share their work with their colleagues, peers and friends effortlessly.
by providing them a link to directly access the article, increasing the visibility of the article and its readership.

**How does it work?**

- An author should request access tokens directly through a staff member of Future Medicine, stating the article which they wish to purchase the tokens for.
- Once payment has been processed, the access tokens are immediately available for activation. The author will receive an automated e-mail that contains the details of how to share the access tokens with their colleagues, peers and friends - including suggested text which they can use as the base for any e-mail they might send.
- Each user who wishes to access the content must be provided with the activation link (contained in the e-mail the author receives) - in order to access the content, they must simply click on the link, then register (or login, if already a registered user) and the content will be available to them.
- There is no time limit within which the tokens must be activated, so there is no pressure on the author to ensure the content is accessed immediately.
- Once all the access tokens have been used, additional bundles of 50 can be purchased and the author can continue to distribute his content in the same way as described above.

**Costs**

Access tokens can be purchased in bundles of 50 at a time at a cost of **£105 per 50 tokens**, which is very cost effective compared with a single user purchasing a single pay-per-view article. Therefore, an author can share his work at a cost of only £2 per person – with no expiry date.